(function(){
			var content_array=["<p><strong>About Syneron<\/strong>&nbsp;<\/p>\r\n<p>Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. &nbsp;The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. &nbsp;<\/p>\r\n<p>Founded in 2000, the corporate, R&amp;D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&amp;D and manufacturing operations in the U.S. &nbsp;The company markets, services and supports its products in 86 countries. &nbsp;It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.<\/p>\r\n<p>For additional information, please visit <a rel=\"nofollow\" href=\"http:\/\/www.syneron-candela.com\/\" target=\"_blank\">http:\/\/www.syneron-candela.com\/<\/a>.<\/p>\r\n<p><strong>Forward-Looking Statements<\/strong>&nbsp;<\/p>\r\n<p>This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the&nbsp;SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.<\/p>\r\n<p><strong>Contacts:<\/strong>&nbsp;<\/p>\r\n<p>Zack Kubow<br \/> The Ruth Group<br \/> +1-646-536-7020<br \/> <a rel=\"nofollow\" href=\"mailto:zkubow@theruthgroup.com\" target=\"_blank\">zkubow@theruthgroup.com<\/a><\/p>\r\n<p>Hugo Goldman<br \/> Chief Financial Officer<br \/> <a rel=\"nofollow\" href=\"mailto:Hugo.Goldman@syneron.com\" target=\"_blank\">Hugo.Goldman@syneron.com<\/a><\/p>\r\n<p>Syneron Medical - Public Relations<br \/> <a rel=\"nofollow\" href=\"mailto:pr@syneron.com\" target=\"_blank\">pr@syneron.com<\/a><\/p>\r\n<p>MELISSA KELZ COMMUNICATIONS,INC - +1-646-450-5359<br \/> Melissa Ben-Yoseph - <a rel=\"nofollow\" href=\"mailto:Melissa@kelzpr.com\" target=\"_blank\">Melissa@kelzpr.com<\/a>&nbsp;<br \/> Patty Mathews - <a rel=\"nofollow\" href=\"mailto:Pattymathews@kelzpr.com\" target=\"_blank\">Pattymathews@kelzpr.com<\/a><\/p>"];
			$("#dvExtra").html(content_array[0]);})();